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OBJECTIVES: to estimate economic consequences and
patients acceptance of a program proposing a switch
toward self-injection of a recombinant Human erythro-
poïetin (r-HuEPO) NeoRecormon with Reco-Pen® in a
population of adult patients on dialysis. METHODS: A
cost-minimisation study was performed in a societal 
perspective to assess the economic consequences of the
program proposing Reco-Pen®, to facilitate self-injection
in patients requiring a treatment with r-HuEPO. A
random national sample of French patients in mainte-
nance dialysis or in pre-dialysis were selected. A nurse
was dedicated in each centre to educate and assist patients
during the study period. Direct costs of injecting r-
HuEPO before and after the program were estimated
including purchase of the device and erythropoïetin, time
spent by nurses for injection and education of patients or
caregivers. Data were collected on all relevant items ret-
rospectively and prospectively during a 2-month follow
up period. An acceptance study was conducted including
self-evaluation of pain during injection, easiness of use
and satisfaction. RESULTS: One hundred twenty-four
patients in 42 centres were enrolled in Fall 2001. Eighty-
seven percent of patients were in maintenance therapy
and the rest in correction phase. The satisfaction scores
were positive in 80% of patients in terms of improved
autonomy and comfort and 93% declared themselves
ready to go on using the pen. The self-injection rates grew
from 21% to 53%. The switch to Reco-Pen® of 100
patient x year was associated with an economic gain of
€22,449 broken down as following: €18,725 corre-
sponding to the beneﬁt on r-HuEPO purchase cost,
€3,500 corresponding to the costs avoided by reducing
the number of injections performed by ofﬁce-based
nurses, and €224 due to the reduction of total time spent
by nurses in the centres. CONCLUSIONS: The short-
term acceptance of self-injection with Reco-Pen® in a
program proposing the assistance of dedicated nurses is
high and associated with an overall economic beneﬁt.
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TIVES: Because the outcomes and cost of caring for
patients with ESRD are of major concern, we analyzed
claims data of patients receiving exclusively either
Calcium Acetate (CA) or Sevelamer HCl (SHCl).
METHODS: From the California Medicaid (Medi-Cal)
program we compared 1401 ESRD patients who were
prescribed CA and 192 who were prescribed SHCl during
a 2-year period. RESULTS: For this population, the
median daily dose and cost were 4447mg ($0.55) for CA
and 4030mg for SHCl ($2.88), a signiﬁcant difference by
multivariate regression analysis that controlled for patient
demographics, co-morbidities, hospital admissions, and
time on binder. Not unexpectedly, comorbid conditions
such as COPD, diabetes, heart disease, and hypertension
were signiﬁcantly associated with costs and number of
hospital admissions. However, in patients who had been
prescribed binder for at least 12 months, there was no
statistically signiﬁcant association between choice of
binder, cardiovascular and other co-morbidities, down-
stream medical resource utilization or costs. Moreover,
there was no difference between the binders with regard
to time to ﬁrst hospitalization as well as the number of
hospital admissions. For a hypothetical cohort of 1000
ESRD patients treated over a 2-year period, the use of CA
as a ﬁrst-line agent, switching to SHCl only patients who
become hypercalcemic, would save almost $1.4 million
with no change in patient morbidity. Savings would be
substantially greater if the same approach is followed for
the entire US dialysis population. CONCLUSION: The
choice of phosphate binder does not have a signiﬁcant
impact on the medical costs (except cost of phosphate
binder), or number of hospitalizations, or time to hospi-
talization during follow-up for patients with ESRD.
However, implementing a 2-stage strategy for phosphate
binders has the potential to signiﬁcantly reduce the 
cost of managing hyperphosphatemia in ESRD patients
without having any detrimental effects on this 
population.
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OBJECTIVE: To report comparisons of the sensitivity 
to change between a condition-speciﬁc quality-of-life
measure (I-QOL, speciﬁc to urinary incontinence) and 
a generic health status measure (SF-36). METHODS:
Incontinent female patients completed the I-QOL and the
SF-36 measures at screening, pre-treatment, and four sub-
sequent follow-up visits during participation in a multi-
center, double-blind, placebo-controlled randomized trial
to assess the efﬁcacy of duloxetine in the treatment of
patients with stress and mixed incontinence. Sensitivity
analyses were conducted using baseline and week 6 data
(or last observation carried forward if participant was an
early dropout). Only responders to stress pad test (25%
decrease), incontinent episodes (25% decrease) and per-
ceived global impression (a little better) were evaluated.
I-QOL scores and SF-36 scores are both transformed onto
a 0 – 100-point scale. RESULTS: For individuals having
a decrease in pad weight of at least 25%, change scores
of the SF-36 ranged from 0 (General Health) to 4 points
(Bodily Pain, Physical Functioning, Role Emotional, and
